Proton pump inhibitors and clopidogrel: an association to avoid?

Area of Science:

• Cardiology
• Pharmacology
• Gastroenterology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard post-acute coronary syndrome or stent implantation.
• Gastrointestinal (GI) bleeding risk necessitates co-administration of proton pump inhibitors (PPIs) with DAPT.
• Ex vivo studies suggest PPIs may diminish clopidogrel's antiplatelet efficacy, raising safety concerns.

Purpose of the Study:

• To evaluate the clinical significance of the interaction between proton pump inhibitors (PPIs) and clopidogrel.
• To address conflicting results from previous clinical trials on PPI-clopidogrel interactions.
• To determine the cardiovascular safety of co-administering PPIs with clopidogrel.

Main Methods:

• Review of existing clinical trials investigating PPI-clopidogrel interactions.
• Analysis of methodological limitations in prior studies.
• Identification of the need for large-scale, prospective, randomized, placebo-controlled trials.

Main Results:

• Existing clinical trials yield conflicting results regarding PPI-clopidogrel interactions.
• Methodological critiques of available studies highlight significant limitations.
• The definitive prospective trial (Clopidogrel and the Optimization of GI Events Trial) was prematurely halted.

Conclusions:

• The clinical impact of PPI-clopidogrel interaction remains unresolved.
• Cardiovascular safety concerns associated with this combination cannot be excluded.
• Provisional use of PPIs with clopidogrel is recommended only for high-risk bleeding patients, avoiding potent CYP2C19 inhibitors like omeprazole and esomeprazole.